Xcel Research LLC – FDA Warning Letter, Dec 10, 2024

On December 10, 2024, the FDA issued a Warning Letter to Andrew Pierce of Xcelpeptides.com following an October 2024 review of their website. The FDA observed that Xcelpeptides.com offers various products for sale in the U.S., including “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN.”

The FDA determined these products are unapproved new drugs, introduced or delivered for introduction into interstate commerce, violating sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). Despite labeling stating "FOR RESEARCH USE ONLY" and "NOT INTENDED FOR HUMAN USE," the FDA found evidence on the website establishing the products' intended use as drugs for human use. These products are considered drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), as they are intended to prevent, treat, or cure disease conditions and/or affect